1Y Close · As of Aug 26, 2026
MYUNGIN PHARM operates in the Pharmaceuticals sector.
Legal name: MYUNGIN PHARM.CO., LTD
In fiscal year 2025, MYUNGIN PHARM (317450) reported revenue of 287.3 billion KRW, up 6.6% from 269.4 billion KRW a year earlier.
Operating profit was 92.5 billion KRW and net income was 81.4 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 676.7 billion KRW, with a P/B of 0.85.
These figures can be verified in the DART filing (receipt no. 20260325001031).
Recent Filings
Semi-Annual Report (2026.06)
Operating (Preliminary) Earnings (Fair Disclosure)
Checks
No items require attention at this time.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-13 | Semi-Annual Report (2026.06) |
| 2026-07-31 | Operating (Preliminary) Earnings (Fair Disclosure) |